Recent studies have unveiled that renal cancer cells harboring SETD2 mutations or downregulated SETD2 expression are highly sensitive to histone demethylase inhibitors (HDMIs) in both in vitro and in vivo models 76-77. This evidence concerns the gene SETD2 and renal carcinoma.